Špeciálne projekty
With an absolute specificity, affinity and the highest avidity possible, the monospecific rabbit clonal antibodies introduce a new level of quality for antibodies applied in basic, clinical research, and human clinical diagnostics (IHC-P and/or ELISA). DB Biotech’s original “in vitro cloning” approach is especially recommended for the difficult targets where the standard monoclonal technology fails.
Proposed service
Structural analysis of the antigen (protein or peptide) molecule, design of specific immunogenic peptide with an original and unique epitope.
The antigen is analyzed by a 18-22 step protocol, which includes the primary, secondary and tertiary structure analysis, possible protein/protein interaction domains, regulatory post-translational modifications, protein truncations, etc. The outcome of this analysis is an original immunogenic peptide (15-25 aminoacid residues), which is used to immunize the rabbits.
Crude rabbit antiserum preparation
Standard protocol:
- synthesis of immunogenic peptide
- conjugation with carrier protein
- rabbit immunization with two consequent boosts
- crude antiserum preparation
In vitro cloning, preparation of monospecific fraction of rabbit IgGs corresponding to one single original epitope of antigen molecule.
Standard protocol:
- in vitro cloning, preparation of several unique homogenous fractions of IgGs recognizing each monospecifically one single and previously targeted epitope on the antigen molecule
- detailed testing of affinity, specificity and avidity of the obtained clones
- selection of the best clone
- setup of a detailed applicational protocol for the final clone use
In order to prepare our price offer for your project, please send us the name of the target protein (UniProt ortholog), or specific post-translational modification, which should be clearly recognized and/or quantified by a clonal antibody.
The minimum quantity of a pure clonal antibody is 10ml (usually 10mg of pure monospecific clonal IgGs), with the minimum dilution 1:2,000 for Western blot application; 1:100-1:500 for IHC-P application.
Ako postupujeme pri vývoji protilátok
Pri vývoji protilátok postupujeme ako aj pri komunikácii s klientom postupujeme novým spôsobom. V prvom rade naša firma konzultuje s klientom použitie dizajnovanej protilátky. Proteín voči ktorému má byť protilátka produkovaná je dôkladne analyzovaný z hľadiska vyšších štruktúr a ďalších aspektov proteomickej analýzy.
Dizajnovaný peptid je použitý na produkciu polyklonálnej anti-peptidovej protilátky. Výsledný preparát najvyššej možnej čistoty, klón čistej imunoglobulínovej frakcie je pripravený zo surového antiséra pomocou novej originálnej technológie, ktorá je naším chráneným know-how.